CAT-1004, a chemical entity, is a conjugate of the essential omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate.
The trial is intended to assess the safety, tolerability and pharmacokinetic profile of CAT-1004 in healthy adult subjects.
During the course of the study, nearly 60 subjects will receive a single dose of CAT-1004 or placebo via oral administration.
Preclinical studies have demonstrated that essential omega-3 fatty acid and salicylate exhibit anti-inflammatory activity.
Catabasis chief medical officer Joanne M. Donovan said CAT-1004 has the potential to improve insulin sensitivity and glucose homeostasis.